Endocrine Abstracts

Introduction: Primary tumours in some patients with metastatic neuroendocrine tumors (NET) cannot be found by conventional imaging as CT, MRI and scintigraphy. 68Ga-DOTATOC PET/CT (68Ga-PET) appears to have superior sensitivity, specifity, and better resolution than 99mTC-octreotide SPECT/TC (SSTR scintigraphy) and can improve decision-making process, however its cost is higher, and its availability is limited.Aims: Evalu...

Medical treatment of acromegaly is currently performed through a trial-error manner using somatostatin receptor ligands (SRLs) as first-line drugs. Average SRLs response is seen in 50% of cases; subsequent drugs are indicated following clinical judgement. Some biomarkers either before or after surgical failure have been reported to predict SRLs response, including intensity in T2 weighted MRI, short acute octreotide test (sAOT), and different molecules such as SST2 and E-cadhe...

We previously described a short version of the acute octreotide test (sAOT) for predicting somatostatin receptor ligands (SRLs) response in patients with acromegaly1. In the present work, we prospectively reassess the sAOT ability to identify SRLs response in patients from the ACROFAST study using the current GH standards and control criteria and we also correlate sAOT values with E-cadherin tumor expression. Methods: Patients from the ACROFAS...